...1	Repeated ID	PERSON_ID	OUT_DTL_CD_DESC	OUT_CD_DESC	OUT_CNSR_CD_DESC	COHORT_CD_DESC	Therapy	Survival_Analyses	Line_of_therapy	Overall_survival_censor	Overal_survival_months	OUT_TIME_AT_RISK_UNIT_CD_DESC	COHORT_CD	lot_sub	lot_cat	lot_line_cd_desc	out_surgery	LOT_GRP	lot_type	phase_cd_desc	cohort_cd	lot_rxcnt	phase_sub_cd_desc	lot_start_dt	lot_end_dt	flag_KRAS_Codon_12	flag_KRAS_Codon_13	flag_KRAS_Codon_61	flag_NRAS_Codon_61	flag_KRAS_G12A	flag_KRAS_G12C	flag_KRAS_G12D	flag_KRAS_G12V	flag_KRAS_G12R	flag_KRAS_G12S	flag_KRAS_G13D	flag_KRAS_Q61H	flag_NRAS_Q61K	flag_NRAS_Q61R	flag_DDR_pathway	flag_ChromatinReg_pathway	flag_MAPK_pathway	flag_ATM	flag_MAX	flag_NKX2_1	flag_RBM10	flag_STK11	flag_U2AF1	flag_CDKN2A	flag_TP53	flag_ARID1A	flag_NTRK3	flag_EPHA5	flag_AMER1	flag_RNF43	flag_PIK3CA	flag_APC	flag_SMAD4	flag_KEAP1	flag_DDR_pathway_hotspot	flag_ChromatinReg_pathway_hotspot	flag_MAPK_pathway_hotspot	flag_ATM_hotspot	flag_MAX_hotspot	flag_NKX2_1_hotspot	flag_RBM10_hotspot	flag_STK11_hotspot	flag_U2AF1_hotspot	flag_CDKN2A_hotspot	flag_TP53_hotspot	flag_ARID1A_hotspot	flag_NTRK3_hotspot	flag_EPHA5_hotspot	flag_AMER1_hotspot	flag_RNF43_hotspot	flag_PIK3CA_hotspot	flag_APC_hotspot	flag_SMAD4_hotspot	flag_KEAP1_hotspot
180	Repeat	GENIE-DFCI-000090	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	24.3449691991786	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	41829	42287	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1772	Repeat	GENIE-DFCI-000090	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	6.47227926078029	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42373	42373	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
181	NA	GENIE-DFCI-000146	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	40.8377823408624	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Cisplatin, Etoposide	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42435	42469	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
182	NA	GENIE-DFCI-000309	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.17659137577002	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41737	41821	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
183	Repeat	GENIE-DFCI-000375	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	18.7597535934292	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42274	42400	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1773	Repeat	GENIE-DFCI-000375	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	12.8788501026694	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42453	42754	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
184	NA	GENIE-DFCI-000485	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	4.40246406570842	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42783	42826	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
185	Repeat	GENIE-DFCI-000710	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	37.388090349076	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42359	42814	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1774	Repeat	GENIE-DFCI-000710	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	21.5195071868583	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42842	43439	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1775	NA	GENIE-DFCI-000750	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	0.427104722792608	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41777	41777	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1776	NA	GENIE-DFCI-000815	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	40.8049281314168	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42436	42738	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1777	NA	GENIE-DFCI-000853	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	6.40657084188912	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42469	42565	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
186	NA	GENIE-DFCI-000942	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	53.4537987679671	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41972	42322	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
187	NA	GENIE-DFCI-001205	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	25.7905544147844	Months	4	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42893	43447	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
188	Repeat	GENIE-DFCI-001223	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	46.7515400410678	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42140	42460	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1778	Repeat	GENIE-DFCI-001223	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	34.0041067761807	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42528	42595	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
189	NA	GENIE-DFCI-001461	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	31.2443531827515	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	1	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42720	43216	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0
190	Repeat	GENIE-DFCI-001832	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	38.5379876796715	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42505	42737	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1779	Repeat	GENIE-DFCI-001832	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	28.5831622176591	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42808	43599	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
191	NA	GENIE-DFCI-001956	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	29.4702258726899	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41540	42437	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1780	Repeat	GENIE-DFCI-002010	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	44.878850102669396	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42286	42580	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
2828	Repeat	GENIE-DFCI-002010	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	28.3203285420945	Months	8	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42790	42965	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
192	NA	GENIE-DFCI-002329	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	12.1889117043121	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42390	42453	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
193	NA	GENIE-DFCI-002597	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.38398357289528	Months	4	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	41640	41696	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
194	NA	GENIE-DFCI-002801	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	8.54209445585216	Months	4	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Vinorelbine	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	41554	41733	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2829	Repeat	GENIE-DFCI-002855	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	38.0123203285421	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42062	42123	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3266	Repeat	GENIE-DFCI-002855	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 4th Line of Therapy	IO	IO ; IO + chemo_IO	2	0	34.9897330595483	Months	10	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	10	1	Post-mets	42154	42611	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
195	NA	GENIE-DFCI-003093	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.23819301848049	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41604	41682	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
196	NA	GENIE-DFCI-003118	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	14.1273100616016	Months	4	Antimetabolite	Chemotherapy	Pemetrexed	1	All other	Monotherapy	Post-NGS	4	1	Post-mets	43181	43496	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2830	NA	GENIE-DFCI-003287	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	8.34496919917864	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42018	42233	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
197	NA	GENIE-DFCI-003685	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	7.03080082135524	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42073	42194	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2831	NA	GENIE-DFCI-003808	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	33.347022587269	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	41992	42372	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1781	NA	GENIE-DFCI-003931	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	4.63244353182752	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41551	41570	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
1782	NA	GENIE-DFCI-004049	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	8.24640657084189	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41956	42001	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1783	NA	GENIE-DFCI-004095	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	34.3983572895277	Months	6	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	41792	41903	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
198	Repeat	GENIE-DFCI-004315	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	35.9753593429158	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42178	42958	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1784	Repeat	GENIE-DFCI-004315	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	7.3264887063655	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43050	43196	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2832	Repeat	GENIE-DFCI-004315	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	NA	2	0	0	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	43273	43273	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
199	Repeat	GENIE-DFCI-004325	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	25.5277207392197	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42815	43102	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1785	Repeat	GENIE-DFCI-004325	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	14.6201232032854	Months	6	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	43147	43592	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1786	NA	GENIE-DFCI-004567	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	16.9199178644764	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42577	42691	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1787	Repeat	GENIE-DFCI-005200	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	24.7063655030801	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42843	42843	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2833	Repeat	GENIE-DFCI-005200	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	18.6283367556468	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	43028	43595	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1788	Repeat	GENIE-DFCI-005352	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	9.19917864476386	Months	6	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Docetaxel, Gemcitabine	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	41526	41631	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2834	Repeat	GENIE-DFCI-005352	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	5.3223819301848	Months	8	Other antineoplastic drugs	Chemotherapy	Irinotecan	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	41644	41700	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
3267	Repeat	GENIE-DFCI-005352	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	3.02258726899384	Months	10	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	10	1	Post-mets	41714	41714	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
200	NA	GENIE-DFCI-005715	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	32.5913757700205	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42576	42863	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1789	NA	GENIE-DFCI-005768	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	4.56673511293635	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42028	42075	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
201	Repeat	GENIE-DFCI-006082	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	9.88911704312115	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42722	42759	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1790	Repeat	GENIE-DFCI-006082	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	3.64681724845996	Months	6	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	42912	42954	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1791	NA	GENIE-DFCI-006088	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	21.2895277207392	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42915	43460	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
202	NA	GENIE-DFCI-006255	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	5.68377823408624	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41547	41631	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
203	Repeat	GENIE-DFCI-006321	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	11.9260780287474	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	41892	42039	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1792	Repeat	GENIE-DFCI-006321	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	4.33675564681725	Months	6	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Docetaxel, Gemcitabine	1	All other	Combotherapy	Post-NGS	6	2	Post-mets	42123	42214	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
204	Repeat	GENIE-DFCI-006769	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	13.5687885010267	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41554	41578	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1793	Repeat	GENIE-DFCI-006769	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	11.9260780287474	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41604	41790	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
205	NA	GENIE-DFCI-006855	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.41683778234086	Months	4	Antimetabolite, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Pemetrexed	1	All other	Combotherapy	Post-NGS	4	2	Post-mets	42983	43060	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
206	Repeat	GENIE-DFCI-007234	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	25.0349075975359	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41865	42165	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1794	Repeat	GENIE-DFCI-007234	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	3.41683778234086	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42523	42564	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
207	Repeat	GENIE-DFCI-007288	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.47227926078029	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41765	41806	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1795	Repeat	GENIE-DFCI-007288	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	5.09240246406571	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Gemcitabine	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	41807	41807	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1796	NA	GENIE-DFCI-007425	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	other	NA	2	0	0	Months	6	CDK4/6 inhibitor	Targeted Therapy	Palbociclib	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	41984	41984	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1797	NA	GENIE-DFCI-007812	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	5.28952772073922	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42229	42316	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
208	NA	GENIE-DFCI-007883	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	2.36550308008214	Months	4	Antimetabolite, Plant alkaloids and other natural products, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Paclitaxel, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	4	Post-mets	41990	42014	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
209	NA	GENIE-DFCI-007939	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	1.67556468172485	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	41978	41992	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1798	Repeat	GENIE-DFCI-007997	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	8.37782340862423	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42206	42217	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2835	Repeat	GENIE-DFCI-007997	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	5.65092402464066	Months	8	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42289	42325	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3268	Repeat	GENIE-DFCI-007997	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	1.37987679671458	Months	10	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	10	1	Post-mets	42419	42440	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
210	NA	GENIE-DFCI-008003	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.14373716632443	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41802	41859	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
1799	Repeat	GENIE-DFCI-008106	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	16.8542094455852	Months	6	Antimetabolite, PD-1/PD-L1, Plant alkaloids and other natural products	Chemotherapy, Immune Checkpoint Inhibitors	Docetaxel, Gemcitabine, Nivolumab	0	All other	Combotherapy	Post-NGS	6	3	Post-mets	42555	42828	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2836	Repeat	GENIE-DFCI-008106	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	6.04517453798768	Months	8	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42884	42926	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1800	NA	GENIE-DFCI-008330	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	2.56262833675565	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41912	41954	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1801	Repeat	GENIE-DFCI-008649	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	16.8870636550308	Months	6	Platinum compound	Chemotherapy	Carboplatin	1	Platinum-based chemotherapy without PD-1/PD-L1i	Monotherapy	Post-NGS	6	1	Post-mets	42223	42351	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2837	Repeat	GENIE-DFCI-008649	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	3.08829568788501	Months	8	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	1	All other	Monotherapy	Post-NGS	8	1	Post-mets	42643	42643	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1802	Repeat	GENIE-DFCI-008990	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	10.2833675564682	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42491	42562	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2838	Repeat	GENIE-DFCI-008990	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	3.84394250513347	Months	8	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	8	2	Post-mets	42687	42723	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2839	Repeat	GENIE-DFCI-009324	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	15.3757700205339	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42278	42403	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3269	Repeat	GENIE-DFCI-009324	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	8.83778234086242	Months	10	Plant alkaloids and other natural products	Chemotherapy	Vinorelbine	0	All other	Monotherapy	Post-NGS	10	1	Post-mets	42477	42526	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
211	Repeat	GENIE-DFCI-009630	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	48.2628336755647	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42209	42251	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1803	Repeat	GENIE-DFCI-009630	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	0	28.7145790554415	Months	6	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42804	42839	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2840	Repeat	GENIE-DFCI-009630	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	22.735112936345	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42986	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
212	Repeat	GENIE-DFCI-009949	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	18.0041067761807	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42105	42203	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1804	Repeat	GENIE-DFCI-009949	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	1.1170431211499	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42619	42619	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1805	Repeat	GENIE-DFCI-010140	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	27.8932238193018	Months	6	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	42379	42566	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2841	Repeat	GENIE-DFCI-010140	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	16.0328542094456	Months	8	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42740	43034	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2842	NA	GENIE-DFCI-010481	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.6611909650924	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42403	42403	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
213	Repeat	GENIE-DFCI-011037	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	41.2320328542094	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42180	42444	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
1806	Repeat	GENIE-DFCI-011037	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	32.1971252566735	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42455	42819	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
214	NA	GENIE-DFCI-011193	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	16.394250513347	Months	4	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Pembrolizumab, Pemetrexed	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	43179	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
215	NA	GENIE-DFCI-011254	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	40.9034907597536	Months	4	CTLA-4, PD-1/PD-L1	Immune Checkpoint Inhibitors	Ipilimumab, Nivolumab	0	Combination immune checkpoint inhibitor	Combotherapy	Post-NGS	4	2	Post-mets	42348	42803	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
216	NA	GENIE-DFCI-011383	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.96098562628337	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42163	42289	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1807	NA	GENIE-DFCI-011496	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	42.3819301848049	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42365	43143	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
217	NA	GENIE-DFCI-011638	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	11.7289527720739	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42489	42811	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
218	NA	GENIE-DFCI-024083	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	1.37987679671458	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	43129	43150	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
219	NA	GENIE-DFCI-024181	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	37.7494866529774	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42429	42492	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
220	Repeat	GENIE-DFCI-024377	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	22.9322381930185	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42593	42655	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1808	Repeat	GENIE-DFCI-024377	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	20.8624229979466	Months	6	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	6	3	Post-mets	42656	43216	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
221	NA	GENIE-DFCI-024630	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	5.12525667351129	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42931	42966	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
222	NA	GENIE-DFCI-032021	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	16.8870636550308	Months	4	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42722	42722	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1809	Repeat	GENIE-DFCI-036418	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	3.51540041067762	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42766	42808	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2843	Repeat	GENIE-DFCI-036418	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	0	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42873	42873	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
223	Repeat	GENIE-DFCI-036434	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	10.5790554414784	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42502	42761	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1810	Repeat	GENIE-DFCI-036434	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	1.28131416837782	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42785	42798	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2844	NA	GENIE-DFCI-036438	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.62833675564682	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42654	42672	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
224	NA	GENIE-DFCI-036717	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	4.82956878850103	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42603	42645	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
225	NA	GENIE-DFCI-036764	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	37.1252566735113	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Nivolumab, Pemetrexed	1	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42548	43318	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
226	Repeat	GENIE-DFCI-036785	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	18.9568788501027	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42712	42775	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1811	Repeat	GENIE-DFCI-036785	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	8.93634496919918	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43017	43038	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1812	Repeat	GENIE-DFCI-036820	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	9.00205338809035	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42963	43012	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
2845	Repeat	GENIE-DFCI-036820	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	7.06365503080082	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	43022	43112	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
3270	Repeat	GENIE-DFCI-036820	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	1.80698151950719	Months	10	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	10	2	Post-mets	43182	43222	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
227	Repeat	GENIE-DFCI-037068	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	15.047227926078	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42401	42485	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
1813	Repeat	GENIE-DFCI-037068	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	11.4332648870637	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42511	42826	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
2846	Repeat	GENIE-DFCI-037068	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	other	NA	2	0	0	Months	8	CDK4/6 inhibitor	Targeted Therapy	Palbociclib	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42859	42859	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
228	NA	GENIE-DFCI-037196	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	18.2012320328542	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42753	42837	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1814	NA	GENIE-DFCI-037245	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	6.4394250513347	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42665	42735	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
229	Repeat	GENIE-DFCI-037702	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	other	NA	1	0	35.3511293634497	Months	4	CDK4/6 inhibitor, PD-1/PD-L1	Immune Checkpoint Inhibitors, Targeted Therapy	Abemaciclib, Pembrolizumab	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42516	42599	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1815	Repeat	GENIE-DFCI-037702	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	32.394250513347	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42606	43559	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
230	Repeat	GENIE-DFCI-037708	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	12.7474332648871	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42557	42660	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1816	Repeat	GENIE-DFCI-037708	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	6.34086242299795	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42752	42912	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
231	NA	GENIE-DFCI-038675	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	29.5359342915811	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42779	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
232	Repeat	GENIE-DFCI-038728	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	17.6755646817248	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42572	42698	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1817	Repeat	GENIE-DFCI-038728	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	13.0759753593429	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42712	43076	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
233	NA	GENIE-DFCI-040848	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	18.299794661191	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42991	43163	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1818	Repeat	GENIE-DFCI-050704	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	7.98357289527721	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42536	42619	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2847	Repeat	GENIE-DFCI-050704	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	2.95687885010267	Months	8	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	8	2	Post-mets	42689	42728	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3271	Repeat	GENIE-DFCI-050704	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 4th Line of Therapy	other	NA	2	0	0	Months	10	CDK4/6 inhibitor	Targeted Therapy	Palbociclib	1	All other	Monotherapy	Post-NGS	10	1	Post-mets	42779	42779	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
234	Repeat	GENIE-DFCI-050785	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	10.9733059548255	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42593	42785	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1819	Repeat	GENIE-DFCI-050785	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	3.74537987679671	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42813	42813	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
235	NA	GENIE-DFCI-050941	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	1.41273100616016	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42566	42591	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
236	NA	GENIE-DFCI-051008	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	26.4147843942505	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42544	42666	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
237	NA	GENIE-DFCI-051223	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	7.45790554414784	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Gemcitabine, Pembrolizumab	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42586	42797	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
238	NA	GENIE-DFCI-051419	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	other	NA	1	1	13.6016427104723	Months	4	CDK4/6 inhibitor, PD-1/PD-L1	Immune Checkpoint Inhibitors, Targeted Therapy	Abemaciclib, Pembrolizumab	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42744	43134	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
239	Repeat	GENIE-DFCI-052981	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	13.4702258726899	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42749	42770	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1820	Repeat	GENIE-DFCI-052981	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	11.4989733059548	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42809	42870	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2848	Repeat	GENIE-DFCI-052981	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	6.50513347022587	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab, Vinorelbine	0	All other	Combotherapy	Post-NGS	8	3	Post-mets	42961	43108	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
240	NA	GENIE-DFCI-053387	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	35.8767967145791	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42430	42808	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
241	Repeat	GENIE-DFCI-076483	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	5.5523613963039	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42721	42868	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1821	Repeat	GENIE-DFCI-076483	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	other	NA	2	0	0	Months	6	CDK4/6 inhibitor	Targeted Therapy	Palbociclib	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	42890	42890	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
242	NA	GENIE-DFCI-079773	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	29.9301848049281	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42694	43061	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
243	NA	GENIE-DFCI-084807	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	14.652977412731	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42925	43371	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
244	NA	GENIE-DFCI-089539	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	3.61396303901437	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42864	42929	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1822	NA	GENIE-DFCI-089765	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	4.82956878850103	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42592	42680	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1823	NA	GENIE-DFCI-090054	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	2.06981519507187	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42865	42886	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
245	Repeat	GENIE-DFCI-090219	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	25.6262833675565	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42797	42959	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1824	Repeat	GENIE-DFCI-090219	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	19.3511293634497	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42988	43351	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2849	Repeat	GENIE-DFCI-090219	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	NA	2	0	4.435318275154	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	43442	43442	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
246	NA	GENIE-DFCI-090232	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	2.39835728952772	Months	4	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Nivolumab, Pemetrexed	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42637	42658	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1825	NA	GENIE-DFCI-091891	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	27.6632443531828	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42710	42843	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
247	NA	GENIE-DFCI-092100	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	5.81519507186858	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	43144	43278	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
248	NA	GENIE-DFCI-092204	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	23.5893223819302	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42960	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
249	NA	GENIE-DFCI-096961	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	0.952772073921971	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	43067	43067	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
250	NA	GENIE-DFCI-102617	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	6.47227926078029	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	43301	43498	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
251	NA	GENIE-DFCI-108464	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	2.23408624229979	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42794	42862	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2850	Repeat	GENIE-DFCI-111327	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	4.73100616016427	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42923	42943	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
3272	Repeat	GENIE-DFCI-111327	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.56262833675565	Months	10	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	10	1	Post-mets	42989	43023	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
252	NA	GENIE-DFCI-118012	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	3.90965092402464	Months	4	PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42798	42875	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2851	NA	GENIE-MSK-P-0000233	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	13.0102669404517	Months	8	Antimetabolite, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Pemetrexed	1	All other	Combotherapy	Post-NGS	8	2	Post-mets	41657	41688	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
253	NA	GENIE-MSK-P-0000299	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	3.44969199178645	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41437	41493	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
254	NA	GENIE-MSK-P-0000344	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	10.1519507186858	Months	4	Plant alkaloids and other natural products, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Paclitaxel	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42711	42910	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
255	Repeat	GENIE-MSK-P-0000622	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.83367556468172	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41619	41683	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1826	Repeat	GENIE-MSK-P-0000622	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	3.84394250513347	Months	6	Antimetabolite, PD-1/PD-L1, Plant alkaloids and other natural products	Chemotherapy, Immune Checkpoint Inhibitors	Gemcitabine, Pembrolizumab, Vinorelbine	0	All other	Combotherapy	Post-NGS	6	3	Post-mets	41710	41775	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
256	Repeat	GENIE-MSK-P-0000756	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.25256673511294	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41701	41722	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1827	Repeat	GENIE-MSK-P-0000756	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	1.64271047227926	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41750	41792	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
257	Repeat	GENIE-MSK-P-0000989	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.23819301848049	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	41759	41802	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1828	Repeat	GENIE-MSK-P-0000989	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	0.985626283367556	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	41858	41872	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
258	Repeat	GENIE-MSK-P-0001550	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	63.3100616016427	Months	4	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Vinorelbine	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	41600	41628	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1829	Repeat	GENIE-MSK-P-0001550	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	19.1540041067762	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42944	42944	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2852	Repeat	GENIE-MSK-P-0001550	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	0	10.1190965092402	Months	8	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	43219	43345	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
3273	Repeat	GENIE-MSK-P-0001550	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 4th Line of Therapy	chemo	NA	2	0	4.435318275154	Months	10	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	10	2	Post-mets	43392	43422	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1830	NA	GENIE-MSK-P-0002001	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	2.33264887063655	Months	6	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	41753	41753	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
1831	Repeat	GENIE-MSK-P-0002444	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	9.98767967145791	Months	6	Antimetabolite, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Gemcitabine, Pemetrexed	1	All other	Combotherapy	Post-NGS	6	3	Post-mets	41756	41925	1	1	0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2853	Repeat	GENIE-MSK-P-0002444	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	3.87679671457906	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	41942	41997	1	1	0	0	0	1	0	0	0	0	1	0	0	0	1	1	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
259	NA	GENIE-MSK-P-0003709	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	12.911704312115	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42391	42669	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
260	Repeat	GENIE-MSK-P-0003964	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	18.9568788501027	Months	4	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Vinorelbine	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	41726	41831	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1832	Repeat	GENIE-MSK-P-0003964	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	10.217659137577	Months	6	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	6	1	Post-mets	41992	42146	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2854	Repeat	GENIE-MSK-P-0003964	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	4.07392197125257	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42179	42249	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3274	Repeat	GENIE-MSK-P-0003964	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	0.0657084188911704	Months	10	Plant alkaloids and other natural products	Chemotherapy	Paclitaxel	0	All other	Monotherapy	Post-NGS	10	1	Post-mets	42301	42301	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
261	Repeat	GENIE-MSK-P-0004890	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	23.4579055441478	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	41888	42110	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1833	Repeat	GENIE-MSK-P-0004890	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	9.23203285420944	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42321	42364	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2855	Repeat	GENIE-MSK-P-0004890	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	0	6.96509240246407	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42390	42469	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1834	NA	GENIE-MSK-P-0005252	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.13552361396304	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42357	42412	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1835	NA	GENIE-MSK-P-0005848	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	14.6858316221766	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42422	42850	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
262	Repeat	GENIE-MSK-P-0005851	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	48.5913757700205	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42199	42304	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1836	Repeat	GENIE-MSK-P-0005851	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	45.0102669404517	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42308	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
263	Repeat	GENIE-MSK-P-0005937	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	10.2505133470226	Months	4	Antimetabolite, Other antineoplastic drugs	Chemotherapy	Fluorouracil, Irinotecan	1	All other	Combotherapy	Post-NGS	4	2	Post-mets	43366	43429	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1837	Repeat	GENIE-MSK-P-0005937	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	0	7.45790554414784	Months	6	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Fluorouracil, Gemcitabine, Paclitaxel	1	All other	Combotherapy	Post-NGS	6	3	Post-mets	43451	43678	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
264	Repeat	GENIE-MSK-P-0005975	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.69815195071869	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42515	42558	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1838	Repeat	GENIE-MSK-P-0005975	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.59548254620123	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42579	42619	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
265	NA	GENIE-MSK-P-0006172	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	8.27926078028747	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42206	42360	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1839	Repeat	GENIE-MSK-P-0006221	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	12.8131416837782	Months	6	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Gemcitabine, Nivolumab	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	42178	42485	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2856	Repeat	GENIE-MSK-P-0006221	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	2.33264887063655	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42497	42541	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1840	NA	GENIE-MSK-P-0006343	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	50.0369609856263	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel, Paclitaxel	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	42010	42962	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
266	NA	GENIE-MSK-P-0006474	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	0	Months	4	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42259	42259	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
267	Repeat	GENIE-MSK-P-0006511	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	19.1540041067762	Months	4	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Paclitaxel	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42992	43197	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1841	Repeat	GENIE-MSK-P-0006511	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	0	6.6694045174538	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Gemcitabine	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	43372	43433	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
268	NA	GENIE-MSK-P-0006878	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.94250513347023	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	41991	42013	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
269	NA	GENIE-MSK-P-0007121	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	41.429158110883	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42195	42538	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
270	NA	GENIE-MSK-P-0007320	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	38.9322381930185	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42097	43070	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
271	Repeat	GENIE-MSK-P-0007418	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	45.864476386037	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42130	42193	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1842	Repeat	GENIE-MSK-P-0007418	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	42.6447638603696	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42228	42630	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
272	Repeat	GENIE-MSK-P-0007583	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	13.2731006160164	Months	4	Antimetabolite, Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	41983	42151	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1843	Repeat	GENIE-MSK-P-0007583	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	7.03080082135524	Months	6	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Gemcitabine, Nivolumab	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	42173	42288	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
273	Repeat	GENIE-MSK-P-0008261	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	24.870636550308	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42758	43469	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
1844	Repeat	GENIE-MSK-P-0008261	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	0.82135523613963	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43490	43490	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
274	Repeat	GENIE-MSK-P-0008654	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	31.211498973306	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	4	Post-mets	42728	43222	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1845	Repeat	GENIE-MSK-P-0008654	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	13.6344969199179	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43263	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1846	NA	GENIE-MSK-P-0008848	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	5.35523613963039	Months	6	Antimetabolite, PD-1/PD-L1, Plant alkaloids and other natural products	Chemotherapy, Immune Checkpoint Inhibitors	Docetaxel, Nivolumab, Pemetrexed	0	All other	Combotherapy	Post-NGS	6	3	Post-mets	42441	42560	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1847	NA	GENIE-MSK-P-0008851	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	3.44969199178645	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42440	42525	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
275	NA	GENIE-MSK-P-0008876	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	2.29979466119096	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42226	42247	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
276	Repeat	GENIE-MSK-P-0009161	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	46.7515400410678	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42255	42560	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1848	Repeat	GENIE-MSK-P-0009161	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	35.2854209445585	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42604	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2857	NA	GENIE-MSK-P-0009256	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	1.31416837782341	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42525	42539	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
277	NA	GENIE-MSK-P-0009269	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	1.31416837782341	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Gemcitabine	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42320	42333	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
278	Repeat	GENIE-MSK-P-0009274	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	15.1129363449692	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42086	42315	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1849	Repeat	GENIE-MSK-P-0009274	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	6.60369609856263	Months	6	CTLA-4, PD-1/PD-L1	Immune Checkpoint Inhibitors	Ipilimumab, Nivolumab	0	Combination immune checkpoint inhibitor	Combotherapy	Post-NGS	6	2	Post-mets	42345	42359	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2858	Repeat	GENIE-MSK-P-0009274	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	4.99383983572895	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42394	42457	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1850	NA	GENIE-MSK-P-0009473	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	47.2443531827515	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42232	42704	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
279	Repeat	GENIE-MSK-P-0009476	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	10.2505133470226	Months	4	Antimetabolite, Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Cisplatin, Docetaxel, Gemcitabine	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42132	42265	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1851	Repeat	GENIE-MSK-P-0009476	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	4.73100616016427	Months	6	PD-1/PD-L1, Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Immune Checkpoint Inhibitors, Targeted Therapy	Docetaxel, Nivolumab, Ramucirumab	0	All other	Combotherapy	Post-NGS	6	3	Post-mets	42300	42410	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2859	Repeat	GENIE-MSK-P-0009476	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	NA	2	1	0.657084188911704	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42424	42424	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
280	NA	GENIE-MSK-P-0009591	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	13.700205338809	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	43157	43346	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
281	Repeat	GENIE-MSK-P-0009660	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	26.5133470225873	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42323	42386	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1852	Repeat	GENIE-MSK-P-0009660	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	23.523613963039	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42414	42687	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
282	NA	GENIE-MSK-P-0009837	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	30.9158110882957	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42737	43547	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
283	NA	GENIE-MSK-P-0009862	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	2.43121149897331	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42330	42371	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
284	Repeat	GENIE-MSK-P-0009959	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	21.5195071868583	Months	4	Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42279	42362	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1853	Repeat	GENIE-MSK-P-0009959	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	NA	2	1	18.7597535934292	Months	6	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	3	Post-mets	42363	42523	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2860	Repeat	GENIE-MSK-P-0009959	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	12.8459958932238	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42543	42824	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3275	Repeat	GENIE-MSK-P-0009959	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	3.31827515400411	Months	10	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Docetaxel, Gemcitabine, Vinorelbine	0	All other	Combotherapy	Post-NGS	10	3	Post-mets	42833	42914	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
285	Repeat	GENIE-MSK-P-0010355	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.35112936344969	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42310	42363	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1854	Repeat	GENIE-MSK-P-0010355	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	0.919917864476386	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42384	42398	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
286	Repeat	GENIE-MSK-P-0010385	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	2.95687885010267	Months	4	Antimetabolite	Chemotherapy	Gemcitabine, Pemetrexed	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42372	42400	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1855	Repeat	GENIE-MSK-P-0010385	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	0.427104722792608	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42449	42449	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
287	NA	GENIE-MSK-P-0010601	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	10.776180698152	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	43047	43117	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
288	NA	GENIE-MSK-P-0010610	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	9.00205338809035	Months	4	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42120	42127	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
289	NA	GENIE-MSK-P-0010980	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	12.1889117043121	Months	4	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Atezolizumab, Gemcitabine	1	All other	Combotherapy	Post-NGS	4	2	Post-mets	43277	43565	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
290	NA	GENIE-MSK-P-0011012	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	2.92402464065708	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42310	42338	1	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
291	NA	GENIE-MSK-P-0011125	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	0.459958932238193	Months	4	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Paclitaxel	0	All other	Combotherapy	Post-NGS	4	2	Post-mets	42471	42478	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
292	Repeat	GENIE-MSK-P-0011154	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	26.7433264887064	Months	4	Antimetabolite, Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Paclitaxel, Pemetrexed	0	All other	Combotherapy	Post-NGS	4	3	Post-mets	42374	42689	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1856	Repeat	GENIE-MSK-P-0011154	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	15.6386036960986	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42712	43111	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
293	Repeat	GENIE-MSK-P-0011157	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	14.9486652977413	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	43008	43050	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1857	Repeat	GENIE-MSK-P-0011157	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	NA	2	1	0.459958932238193	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43449	43449	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
294	NA	GENIE-MSK-P-0011453	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	2.06981519507187	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound, VEGF pathway	Chemotherapy, Immune Checkpoint Inhibitors, Targeted Therapy	Bevacizumab, Cisplatin, Nivolumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	4	Post-mets	42136	42193	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
295	NA	GENIE-MSK-P-0012059	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	18.3983572895277	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42167	42544	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1858	Repeat	GENIE-MSK-P-0012458	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	7.12936344969199	Months	6	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Vinorelbine	1	All other	Combotherapy	Post-NGS	6	2	Post-mets	42514	42571	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2861	Repeat	GENIE-MSK-P-0012458	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	4.33675564681725	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42599	42613	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3276	Repeat	GENIE-MSK-P-0012458	Event-Death	OS main	Yes outcome	Patients in the Broad 4th Line of Therapy	chemo	NA	2	1	2.16837782340862	Months	10	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	1	Docetaxel monotherapy	Monotherapy	Post-NGS	10	1	Post-mets	42665	42665	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1859	Repeat	GENIE-MSK-P-0012729	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	10.0862422997947	Months	6	Antimetabolite, PD-1/PD-L1, Platinum compound, VEGF pathway	Chemotherapy, Immune Checkpoint Inhibitors, Targeted Therapy	Bevacizumab, Carboplatin, Nivolumab, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	6	4	Post-mets	42562	42701	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2862	Repeat	GENIE-MSK-P-0012729	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	2.26694045174538	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42800	42856	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1860	NA	GENIE-MSK-P-0012849	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	0.394250513347023	Months	6	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	1	Docetaxel monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42582	42582	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
296	NA	GENIE-MSK-P-0013381	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	2.85831622176591	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42550	42602	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
297	Repeat	GENIE-MSK-P-0013428	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	25.0677618069815	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42844	43012	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1861	Repeat	GENIE-MSK-P-0013428	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo_IO	NA	2	0	16.5585215605749	Months	6	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Atezolizumab, Gemcitabine	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	43103	43306	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2863	Repeat	GENIE-MSK-P-0013428	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	8.04928131416838	Months	8	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Vinorelbine	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	8	2	Post-mets	43362	43607	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
298	NA	GENIE-MSK-P-0014172	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	9.3305954825462	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42577	42843	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
299	NA	GENIE-MSK-P-0015002	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	35.8767967145791	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42468	42619	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1862	NA	GENIE-MSK-P-0015021	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	0.75564681724846	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42750	42771	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1863	Repeat	GENIE-MSK-P-0015348	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	7.81930184804928	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42495	42546	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2864	Repeat	GENIE-MSK-P-0015348	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	5.02669404517454	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel	0	Docetaxel monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42580	42620	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
3277	Repeat	GENIE-MSK-P-0015348	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 4th Line of Therapy	chemo	NA	2	0	3.21971252566735	Months	10	Antimetabolite, Plant alkaloids and other natural products	Chemotherapy	Gemcitabine, Vinorelbine	0	All other	Combotherapy	Post-NGS	10	2	Post-mets	42635	42691	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1864	Repeat	GENIE-MSK-P-0015529	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	6.07802874743327	Months	6	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	3	Post-mets	42667	42765	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2865	Repeat	GENIE-MSK-P-0015529	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	1.93839835728953	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	42793	42849	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
300	NA	GENIE-MSK-P-0015554	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	35.121149897330596	Months	4	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42609	43332	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1865	NA	GENIE-MSK-P-0015667	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	8.04928131416838	Months	6	Antimetabolite, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Pemetrexed	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	42649	42711	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1866	NA	GENIE-MSK-P-0015929	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	5.97946611909651	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42711	42774	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
301	Repeat	GENIE-MSK-P-0016016	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	14.8172484599589	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42357	42442	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1867	Repeat	GENIE-MSK-P-0016016	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	6.17659137577002	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42620	42706	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
302	Repeat	GENIE-MSK-P-0016271	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	7.95071868583162	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42571	42689	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1868	Repeat	GENIE-MSK-P-0016271	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.92402464065708	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42724	42738	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1869	Repeat	GENIE-MSK-P-0016491	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.62833675564682	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42700	42721	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2866	Repeat	GENIE-MSK-P-0016491	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	1.05133470225873	Months	8	Plant alkaloids and other natural products	Chemotherapy	Paclitaxel	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42748	42748	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
303	NA	GENIE-MSK-P-0016521	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.11088295687885	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42628	42763	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1870	NA	GENIE-MSK-P-0016869	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	27.958932238193	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42827	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
304	NA	GENIE-MSK-P-0017224	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.76386036960986	Months	4	Antimetabolite	Chemotherapy	Pemetrexed	0	All other	Monotherapy	Post-NGS	4	1	Post-mets	42684	42684	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1871	NA	GENIE-MSK-P-0017253	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	4.20533880903491	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42662	42704	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
305	Repeat	GENIE-MSK-P-0017842	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	33.1170431211499	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42670	43048	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1872	Repeat	GENIE-MSK-P-0017842	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	20.0082135523614	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43069	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1873	NA	GENIE-MSK-P-0017975	Censored- End of study period	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	22.9979466119097	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42978	43678	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
306	NA	GENIE-MSK-P-0018511	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	1.87268993839836	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42474	42474	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
307	NA	GENIE-MSK-P-0018517	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	2.29979466119096	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42802	42830	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
308	NA	GENIE-MSK-P-0018814	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.05544147843943	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	1	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42584	42606	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1874	NA	GENIE-MSK-P-0019172	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	1.57700205338809	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43030	43051	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
309	NA	GENIE-MSK-P-0019252	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	8.70636550308008	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42901	42925	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2867	NA	GENIE-MSK-P-0019451	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	15.1786447638604	Months	8	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	8	1	Post-mets	43167	43629	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1875	Repeat	GENIE-MSK-P-0020497	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	5.65092402464066	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42949	43020	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2868	Repeat	GENIE-MSK-P-0020497	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	2.62833675564682	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	43041	43074	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
310	NA	GENIE-MSK-P-0020823	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	13.9630390143737	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	43183	43225	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
311	NA	GENIE-MSK-P-0020874	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	3.48254620123203	Months	4	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	43475	43482	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2869	Repeat	GENIE-MSK-P-0020986	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	0	16.2956878850103	Months	8	Antimetabolite	Chemotherapy	Gemcitabine	0	All other	Monotherapy	Post-NGS	8	1	Post-mets	42894	42963	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
3278	Repeat	GENIE-MSK-P-0020986	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 4th Line of Therapy	IO	IO ; IO + chemo_IO	2	0	1.57700205338809	Months	10	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	10	1	Post-mets	43342	43342	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
312	Repeat	GENIE-MSK-P-0021094	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	9.82340862422998	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Cisplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42673	42889	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1876	Repeat	GENIE-MSK-P-0021094	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	1.80698151950719	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Atezolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42917	42953	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
313	Repeat	GENIE-MSK-P-0021224	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	17.1498973305955	Months	4	Antimetabolite, Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Gemcitabine, Paclitaxel, Pemetrexed, Vinorelbine	0	All other	Combotherapy	Post-NGS	4	5	Post-mets	42594	42991	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1877	Repeat	GENIE-MSK-P-0021224	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	2.26694045174538	Months	6	PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Nivolumab	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	43047	43075	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1878	Repeat	GENIE-MSK-P-0021454	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo_IO	IO + chemo_IO	2	1	9.00205338809035	Months	6	Antimetabolite, PD-1/PD-L1	Chemotherapy, Immune Checkpoint Inhibitors	Pembrolizumab, Pemetrexed	0	All other	Combotherapy	Post-NGS	6	2	Post-mets	42800	42897	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2870	Repeat	GENIE-MSK-P-0021454	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo_IO	NA	2	1	5.782340862423	Months	8	Antimetabolite, PD-1/PD-L1, Plant alkaloids and other natural products	Chemotherapy, Immune Checkpoint Inhibitors	Gemcitabine, Pembrolizumab, Vinorelbine	0	All other	Combotherapy	Post-NGS	8	3	Post-mets	42898	43033	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
314	NA	GENIE-MSK-P-0022254	Censored- Investigational product	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	26.4147843942505	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42659	43020	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
315	Repeat	GENIE-MSK-P-0023218	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	7.3264887063655	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42944	42986	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1879	Repeat	GENIE-MSK-P-0023218	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	1	4.63244353182752	Months	6	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	3	Post-mets	43026	43047	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2871	Repeat	GENIE-MSK-P-0023218	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	2.95687885010267	Months	8	Plant alkaloids and other natural products, Platinum compound	Chemotherapy	Carboplatin, Docetaxel, Paclitaxel	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	8	3	Post-mets	43077	43117	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
316	Repeat	GENIE-MSK-P-0023468	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	0	27.5975359342916	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42782	42992	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1880	Repeat	GENIE-MSK-P-0023468	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	0	5.05954825462012	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	43468	43622	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2872	NA	GENIE-MSK-P-0023622	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	chemo_2	2	1	1.87268993839836	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42711	42746	1	0	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
317	NA	GENIE-VICC-323116	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	1.7741273100616	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42658	42658	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
318	NA	GENIE-VICC-326457	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	6.20944558521561	Months	4	PD-1/PD-L1, Plant alkaloids and other natural products, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Paclitaxel, Pembrolizumab	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42795	42963	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
319	Repeat	GENIE-VICC-362210	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	6.24229979466119	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42332	42397	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
1881	Repeat	GENIE-VICC-362210	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	3.48254620123203	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42416	42458	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
1882	NA	GENIE-VICC-367327	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	2.8911704312115	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42051	42114	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
320	NA	GENIE-VICC-441252	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	18.8254620123203	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42935	42976	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1883	Repeat	GENIE-VICC-441252	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 2nd Line of Therapy	chemo	chemo_2	2	0	16.788501026694	Months	6	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	6	2	Post-mets	42997	43018	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2873	Repeat	GENIE-VICC-441252	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	0	15.4743326488706	Months	8	Plant alkaloids and other natural products, VEGF pathway	Chemotherapy, Targeted Therapy	Docetaxel, Ramucirumab	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	43037	43333	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
321	NA	GENIE-VICC-509112	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	0.887063655030801	Months	4	Antimetabolite, Platinum compound, VEGF pathway	Chemotherapy, Targeted Therapy	Bevacizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42152	42152	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
322	NA	GENIE-VICC-588428	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	12.3860369609856	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42344	42605	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
323	NA	GENIE-VICC-649058	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	1	4.69815195071869	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42832	42903	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
324	NA	GENIE-VICC-676204	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	1	1.87268993839836	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Atezolizumab, Carboplatin, Pemetrexed	0	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	42831	42859	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
325	NA	GENIE-VICC-684703	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	chemo_IO	IO + chemo_IO	1	0	9.59342915811088	Months	4	Antimetabolite, PD-1/PD-L1, Platinum compound	Chemotherapy, Immune Checkpoint Inhibitors	Carboplatin, Pembrolizumab, Pemetrexed	1	Platinum-based chemotherapy with PD-1/PD-L1i	Combotherapy	Post-NGS	4	3	Post-mets	43167	43251	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
326	NA	GENIE-VICC-725506	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	4.04106776180698	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42656	42747	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
327	NA	GENIE-VICC-746498	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	3.87679671457906	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42773	42869	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
328	Repeat	GENIE-VICC-806016	Event-Death	OS main	Yes outcome	Patients in the Broad 1st Line of Therapy	chemo	chemo_1	1	1	12.0574948665298	Months	4	Antimetabolite, Platinum compound	Chemotherapy	Carboplatin, Pemetrexed	0	Platinum-based chemotherapy without PD-1/PD-L1i	Combotherapy	Post-NGS	4	2	Post-mets	42346	42396	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1884	Repeat	GENIE-VICC-806016	Event-Death	OS main	Yes outcome	Patients in the Broad 2nd Line of Therapy	IO	IO ; IO + chemo_IO	2	1	9.3305954825462	Months	6	PD-1/PD-L1	Immune Checkpoint Inhibitors	Nivolumab	0	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	6	1	Post-mets	42429	42457	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
2874	Repeat	GENIE-VICC-806016	Event-Death	OS main	Yes outcome	Patients in the Broad 3rd Line of Therapy	chemo	NA	2	1	7.03080082135524	Months	8	Plant alkaloids and other natural products	Chemotherapy	Docetaxel, Vinorelbine	0	All other	Combotherapy	Post-NGS	8	2	Post-mets	42499	42632	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
329	NA	GENIE-VICC-842300	Censored- End of follow-up	OS main	No outcome/censored	Patients in the Broad 1st Line of Therapy	IO	IO ; IO + chemo_IO	1	0	17.1170431211499	Months	4	PD-1/PD-L1	Immune Checkpoint Inhibitors	Pembrolizumab	1	PD-1/PD-L1i monotherapy	Monotherapy	Post-NGS	4	1	Post-mets	42955	43176	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
